Evaluation of short-course durvalumab combined with dose-dense EC in the neoadjuvant setting for locally advanced luminal B/HER2(-) or triple-negative breast cancer. - Devaux A; Beniuga G; Delrée P; Quaghebeur C; Henry S; Van Bockstal M; Galant C; Lefevre S; Korman D; Verschaeve V; Lonchay C; D'Hondt L; et al. (Breast cancer research : BCR, 2025)